- Home
- PBPB vs STRO Comparison
PBPB vs STRO Comparison
Compare PBPB & STRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PBPB
- STRO
- Stock Information
- Founded
- PBPB 1977
- STRO 2003
- Country
- PBPB United States
- STRO United States
- Employees
- PBPB N/A
- STRO N/A
- Industry
- PBPB Restaurants
- STRO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PBPB Consumer Discretionary
- STRO Health Care
- Exchange
- PBPB Nasdaq
- STRO Nasdaq
- Market Cap
- PBPB 313.6M
- STRO 172.8M
- IPO Year
- PBPB 2013
- STRO 2018
- Fundamental
- Price
- PBPB $9.46
- STRO $1.97
- Analyst Decision
- PBPB Strong Buy
- STRO Strong Buy
- Analyst Count
- PBPB 3
- STRO 7
- Target Price
- PBPB $15.67
- STRO $12.14
- AVG Volume (30 Days)
- PBPB 117.2K
- STRO 1.4M
- Earning Date
- PBPB 11-07-2024
- STRO 11-13-2024
- Dividend Yield
- PBPB N/A
- STRO N/A
- EPS Growth
- PBPB 641.95
- STRO N/A
- EPS
- PBPB 1.25
- STRO N/A
- Revenue
- PBPB $471,719,000.00
- STRO $160,955,000.00
- Revenue This Year
- PBPB N/A
- STRO N/A
- Revenue Next Year
- PBPB $3.71
- STRO N/A
- P/E Ratio
- PBPB $7.48
- STRO N/A
- Revenue Growth
- PBPB N/A
- STRO 230.90
- 52 Week Low
- PBPB $6.28
- STRO $1.70
- 52 Week High
- PBPB $14.36
- STRO $6.13
- Technical
- Relative Strength Index (RSI)
- PBPB 48.11
- STRO 31.89
- Support Level
- PBPB $8.98
- STRO $1.70
- Resistance Level
- PBPB $10.19
- STRO $3.01
- Average True Range (ATR)
- PBPB 0.34
- STRO 0.20
- MACD
- PBPB -0.11
- STRO -0.01
- Stochastic Oscillator
- PBPB 35.29
- STRO 20.61
About PBPB Potbelly Corporation
Potbelly Corp owns and franchises hundreds of limited-service restaurants specializing in sandwiches and salads, shakes. The menu includes toasty sandwiches, signature salads, soups, chili, sides, desserts, and, in breakfast locations it serves breakfast sandwiches and steel-cut oatmeal. majority of its locations are company-owned and located in the United States, with Illinois and Texas housing far more locations than any other state. The company has franchise partners in a number of countries. Excluding the United States, its franchises are in the Middle East.
About STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers.